Researchers found that chatbots’ responses scored better than oncologists’ responses in terms of overall quality, empathy, and readability. Two of the 3 chatbots also produced responses that were more ...

Minimal residual disease surveillance may predict long-term progression and survival outcomes in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant.

Some researchers are working to sniff out fraud and restore integrity to their field.

The Mark Cuban Cost Plus Drug Company has the potential to reduce Medicare Part D spending for cancer drugs, data suggest.

Adding perioperative nivolumab to neoadjuvant chemotherapy can improve outcomes in patients with non-small cell lung cancer (NSCLC), according to results from the CheckMate 77T trial.

Non-Hispanic Black patients with melanoma present with more advanced disease than non-Hispanic White patients, data suggest.

Merck has decided to discontinue the vibostolimab-pembrolizumab coformulation arm of the phase 3 KeyVibe-010 trial.

Some experts have said greater oversight of laboratory-developed tests will have negative impacts on cancer research and care ...

Trans-inclusive language can help clinicians promote accessible and equitable care in traditional women's health care spaces.

In April, the US Food and Drug Administration announced pipeline updates for several drugs intended to treat cancers.

Experts point to a clear incentivization of quantity, rather than quality, of research output — both with the publishing ...